Current perspectives of <Superscript>14</Superscript>C-isotope measurement in biomedical accelerator mass spectrometry

Accelerator mass spectrometry (AMS) is an extremely sensitive nuclear physics technique developed in the mid-70s for radiocarbon dating of historical artefacts. The technique centres round the use of a tandem Van de Graaff accelerator to generate the potential energy to permit separation of elemental isotopes at the single atom level. AMS was first used in the early 90s for the analysis of biological samples containing enriched ¹⁴C for toxicology and cancer research. Since that time biomedical AMS has been used in the study of (1) metabolism of xenobiotics in animals and humans (2) pathways of drug metabolism (3) biomarkers (4) metabolism of endogenous molecules including vitamins (5) DNA and protein binding studies and (6) clinical diagnosis. A new drug development concept which relies on the ultrasensitivity of AMS known as human microdosing (Phase 0) is being used to obtain early human metabolism information of candidate drugs arising out of discovery. These various aspects of AMS are reviewed in this article and a perspective on future applications of AMS provided.     

Accelerator mass spectrometry of small biological samples

Accelerator mass spectrometry (AMS) is an ultra-sensitive technique for isotopic ratio measurements. In the biomedical field, AMS can be used to measure femtomolar concentrations of labeled drugs in body fluids, with direct applications in early drug development such as Microdosing. Likewise, the regenerative properties of cells which are of fundamental significance in stem-cell research can be determined with an accuracy of a few years by AMS analysis of human DNA. However, AMS nominally requires about 1 mg of carbon per sample which is not always available when dealing with specific body substances such as localized, organ-specific DNA samples. Consequently, it is of analytical interest to develop methods for the routine analysis of small samples in the range of a few tens of microg. We have used a 5 MV Pelletron tandem accelerator to study small biological samples using AMS. Different methods are presented and compared. A (12)C-carrier sample preparation method is described which is potentially more sensitive and less susceptible to contamination than the standard procedures.     

FemtoMolar measurements using accelerator mass spectrometry

Accelerator mass spectrometry (AMS) is an ultra‐sensitive analytical method suitable for the detection of sub‐nM concentrations of labeled biological substances such as pharmaceutical drugs in body fluids. A limiting factor in extending the concentration measurements to the sub‐pM range is the natural ¹⁴C content in living tissues. This was circumvented by separating the labeled drug from the tissue matrix, using standard high‐performance liquid chromatography (HPLC) procedures. As the separated total drug amount is in the few fg range, it is not possible to use a standard AMS sample preparation method, where mg sizes are required. We have utilized a sensitive carbon carrier method where a ¹⁴C‐deficient compound is added to the HPLC fractions and the composite sample is prepared and analyzed by AMS. Using 50 µL human blood plasma aliquots, we have demonstrated concentration measurements below 20 fM, containing sub‐amol amounts of the labeled drug. The method has the immediate potential of operating in the sub‐fM region. Copyright © 2009 John Wiley & Sons, Ltd.     

Quantification of Structural Integrity and Stability Using Nanograms of Protein by Flow-Induced Dispersion Analysis

In the development of therapeutic proteins, analytical assessment of structural stability and integrity constitutes an important activity, as protein stability and integrity influence drug efficacy, and ultimately patient safety. Existing analytical methodologies solely rely on relative changes in optical properties such as fluorescence or scattering upon thermal or chemical perturbation. Here, we present an absolute analytical method for assessing protein stability, structure, and unfolding utilizing Taylor dispersion analysis (TDA) and LED-UV fluorescence detection. The developed TDA method measures the change in size (hydrodynamic radius) and intrinsic fluorescence of a protein during in-line denaturation with guanidinium hydrochloride (GuHCl). The conformational stability of the therapeutic antibody adalimumab and human serum albumin were characterized as a function of pH. The simple workflow and low sample consumption (40 ng protein per data point) of the methodology make it ideal for assessing protein characteristics related to stability in early drug development or when having a scarce amount of sample available.     

Electroactivity of Nonconjugated Proteins and Peptides. Towards Electroanalysis of All Proteins

Present proteomics and biomedicine require sensitive analytical methods for all proteins. Recent progress in electrochemical analysis of peptides and proteins based on their intrinsic electroactivity is reviewed. Tyrosine and/or tryptophan‐containing proteins are oxidizable at carbon electrodes. At mercury electrodes all peptides and proteins (about 13 peptides and >25 proteins were tested) produce chronopotentiometric peak H at nanomolar concentrations. This peak is sensitive to changes in protein structure. Microliter sample volumes are sufficient for the analysis. Electrochemical methods can be used in studies of nucleic acid‐protein interactions and can be applied in biomedicine. Examples of such applications in neurogenerative diseases and cancer are presented.     

On the AMS and EPR Studies of Chinese Cultural Objects

Accelerator mass spectrometry (AMS) is a versatile tool in carbon‐14 dating. In the studies of Chinese paintings and calligraphic works on paper substrates, it is necessary to assess the period of preparation. The precision of AMS measurements has been proven to be reliable for estimation, In conformity with historical background of the art works, AMS can be adapted to assess the age, authenticity, artistic information and conservation requirements. The AMS measurement of Chinese ink rubbing on paper, after OxCal data treatment, gave a result of 1105 ± 30BP. During the course of artistic preparations the paper received extensive impact force which induced the formation of entrapped free radicals. Thus, EPR spectrometry was used to investigate the sample, as well as for a print with an age of 345 ± 40BP by AMS dating and a piece of blank paper from 17^th century to find out the differences in free radical phenomena.     

Accelerator mass spectrometry of <Superscript>129</Superscript>I: Technique and applications

Summary The advantages that accelerator mass spectrometry (AMS) provide for radiocarbon analysis, notably smaller sample sizes and shorter measurement times, also apply to the analysis of ¹²⁹I. In this paper, the requirements for a mass spectrometry system for measuring extremely low concentrations of rare atoms are discussed and these requirements are illustrated using the details of the AMS analysis of ¹²⁹I. As an example of an application of this AMS technology, a series of ¹²⁹I measurements, used to identify isolated events in which radioactivity has been atmospherically transported into the Arctic, is described. Such investigations could not be carried out without the small sample size capability of AMS analysis.     

Current instrumentation for aerosol mass spectrometry

This review describes recently presented instrumental set-ups for aerosol mass spectrometry (AMS), most being suitable for in-situ analysis. AMS allows the analysis of atmospheric aerosol particles within a short time interval and without sample pretreatment, and it is less sensitive to artifact formation than conventional sampling and analytical techniques. Although a quantitative measure of total organic loading can be obtained with some AMS instruments, they currently give only limited information on specific compounds. When the ionization technique produces a large number of fragments for a compound, it becomes impossible to track the original compound. Moreover, at present, there is no commercially available instrument capable of quantitative analysis of chemical compounds in ambient aerosol particles with diameters of 0.003–50 μm and simultaneously offering short time resolution. We pay special attention to the technical and methodological challenges of AMS, whose benefits we demonstrate with selected applications.     

Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies

Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may facilitate drug–drug interaction and dose individualization studies with cytotoxic drugs, without causing harm to patients. Therefore, a highly sensitive bioanalytical assay is required. A reversed-phase ultra-high performance liquid chromatography method was developed to determine pemetrexed concentrations in human ethylenediaminetetraacetic acid–plasma after microdosing. [¹³C₅]-Pemetrexed was used as the internal standard. The sample preparation involved solid-phase extraction from plasma. Detection was performed using MS/MS in a total run time of 9.5 min. The assay was validated over the concentration range of 0.0250–25.0 μg/L pemetrexed. The average accuracies for the assay in plasma were 96.5 and 96.5%, and the within-day and between-day precision in coefficients of variations was <8.8%. Extraction recovery was 59 ± 1 and 55 ± 5% for pemetrexed and its internal standard. Processed plasma samples were stable for 2 days in a cooled autosampler at 10°C. The assay was successfully applied in a pharmacokinetic curve, which was obtained as a part of an ongoing clinical microdosing study.     

One‐step synthesis of polysiloxane graft polyethylene mimic: Non‐expensive compatibilizer for polyethylene/polysiloxane blend

Polysiloxane/polyolefin copolymers have drawn much attention recently and emerged as a new group of functional polyolefin since they possess distinctive properties and find great potential applications in many areas (eg, compatibilizer, processing aid and surface modifier). However, traditional routes to synthesize polysiloxane/polyolefin copolymers generally require multi‐step labor‐consuming procedures. Herein, we report a novel one‐step synthesis of polydimethylsiloxane graft polyethylene (PDMS‐g‐PE) mimics. It was found that PDMS‐g‐PE mimics, namely vinylmethylsiloxane‐dimethylsiloxane‐(C30‐45 alkyl)methylsiloxane copolymers (short for VD‐AMS), could be formed via a one‐step synthetic procedure based on the siloxane equilibrium process between silanol‐terminated vinylmethylsiloxane‐methylsiloxane copolymer and (C30‐45 alkyl)methylsilicone. The chemical structures of VD‐AMS were characterized unambiguously using Fourier transform infrared spectroscopy, nuclear magnetic resonance, gel permeation chromatography, differential scanning calorimetry. The correlation between reaction conditions and the structural parameters of VD‐AMS was established. Based on our experimental results, a plausible mechanism for the synthesis of VD‐AMS was proposed. Scanning electron microscopy micrographs showed that VD‐AMS could function as an efficient compatibilizer for immiscible PE/silicone blend. Given that the precursors of VD‐AMS are commercially available with low prices and that VD‐AMS can be easily synthesized under mild conditions, we believe VD‐AMS can represent as a competitive potential compatibilizer due to its relatively low cost.     

Liquid chromatography/tandem mass spectrometry sensitivity enhancement via online sample dilution and trapping: applications in microdosing and dried blood spot (DBS) bioanalysis

A simple online sample dilution, enrichment, and cleanup technique was developed for sensitive microdosing and dried blood spot (DBS) liquid chromatography/tandem mass spectrometric (LC/MS/MS) bioanalysis. Samples are diluted online with water and enriched in a trap column which is subsequently switched inline with the analytical column. Excellent lansoprazole (in acetonitrile) peak shape is maintained even with an 80‐µL injection. In comparison, similar chromatographic peaks were observed only when a small volume of the same solution, i.e., 1 µL, was injected on a regular high‐performance liquid chromatography (HPLC) system, where an injection of 5 µL resulted in severe peak fronting. A substantial enhancement in sensitivity is realized in the trapping mode using large injection volumes. The trap column is washed at the beginning and at the end of each injection with aqueous and organic solvent respectively to remove matrix components. This ultimately leads to reduction of matrix effects and mass spectrometer noise, thus facilitating the utilization of protein precipitation as the sample preparation for plasma samples. A lower limit of quantitation (LLOQ) of 0.5 pg/mL was demonstrated for lansoprazole in human plasma with a signal‐to‐noise (S/N) ratio of 13 using a 100 µL injection. Excellent intra‐day precision and accuracy were established for lansoprazole in human plasma with good linearity (R² > 0.999) from 0.5 to 500 pg/mL. This level of LLOQ makes LC/MS/MS a practical alternative for microdosing bioanalysis, where the dose is typically 100 times lower than the therapeutic dose. The same technique was applied to quantitate lansoprazole in human whole blood employing DBS technology. With a single 3‐mm punch, i.e. ～2 µL of whole blood or ～1 µL plasma, a LLOQ of 0.1 ng/mL showed sufficient S/N ratio (40) for lansoprazole when 75 µL of extract was injected. In all, the online sample dilution, cleanup, and enrichment technique demonstrated the practical utility of LC/MS/MS in microdosing and DBS bioanalysis. Copyright © 2010 John Wiley & Sons, Ltd.     

Site- and event-specific wastewater-based epidemiology: Current status and future perspectives

Wastewater-based epidemiology (WBE) can provide objective and reliable data to monitor spatio‐temporal patterns of licit and illicit drug use. Numerous studies have been published relating to sampling, sample stability, validation of analytical protocols and the back-calculation of drug consumption. The majority of these studies focus on sampling from municipal sewage treatment plants, but an increasing number of studies have used WBE to monitor community-specific substance use and use during special events. This paper presents a systematic review of published WBE studies of drug use trends in educational institutions and prisons, as well as during music festivals, sporting events, and holidays. A discussion on the application and benefits of using wastewater-based epidemiology in these specific cases is presented together with an examination of current challenges and future perspectives.     

化妆品样品前处理与检测技术研究进展

随着我国经济和人民生活水平的不断提高,作为日常消费品的化妆品产业发展迅猛,其安全性日益受到广泛关注。随之而来的化妆品检测量的大幅增长对检测技术提出了更高的要求。传统样品前处理和检测技术因有机试剂消耗量大,检测通量低、检测周期长已无法满足当前绿色化学发展和高通量检测的需求。对此,科研人员开发了一系列环境友好型前处理技术以及高通量现场快速检测方法,为化妆品质量安全保驾护航。该文综述了当前化妆品样品前处理及检测技术的研究进展,并展望了其发展趋势和应用前景,以期为从事化妆品检测的科研和检验人员提供技术参考。     

Comparison of triple quadrupole,hybrid linear ion trap triple quadrupole,time‐of‐flight and LTQ‐Orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro – amitriptyline and verapamil as model compounds

Liquid chromatography in combination with mass spectrometry (LC/MS) is a superior analytical technique for metabolite profiling and identification studies performed in drug discovery and development laboratories. In the early phase of drug discovery the analytical approach should be both time‐ and cost‐effective, thus providing as much data as possible with only one visit to the laboratory, without the need for further experiments. Recent developments in mass spectrometers have created a situation where many different mass spectrometers are available for the task, each with their specific strengths and drawbacks. We compared the metabolite screening properties of four main types of mass spectrometers used in analytical laboratories, considering both the ability to detect the metabolites and provide structural information, as well as the issues related to time consumption in laboratory and thereafter in data processing. Human liver microsomal incubations with amitriptyline and verapamil were used as test samples, and early‐phase ‘one lab visit only’ approaches were used with all instruments. In total, 28 amitriptyline and 69 verapamil metabolites were found and tentatively identified. Time‐of‐flight mass spectrometry (TOFMS) was the only approach detecting all of them, shown to be the most suitable instrument for elucidating as comprehensive metabolite profile as possible leading also to lowest overall time consumption together with the LTQ‐Orbitrap approach. The latter however suffered from lower detection sensitivity and false negatives, and due to slow data acquisition rate required slower chromatography. Approaches with triple quadrupole mass spectrometry (QqQ) and hybrid linear ion trap triple quadrupole mass spectrometry (Q‐Trap) provided the highest amount of fragment ion data for structural elucidation, but, in addition to being unable to produce very high‐important accurate mass data, they suffered from many false negatives, and especially with the QqQ, from very high overall time consumption. Copyright © 2010 John Wiley & Sons, Ltd.     

Therapeutic Fc‐fusion proteins: Current analytical strategies

Fc‐Fusion proteins represent a successful class of biopharmaceutical products, with already 13 drugs approved in the European Union and United States as well as three biosimilar versions of etanercept. Fc‐Fusion products combine tailored pharmacological properties of biological ligands, together with multiple functions of the fragment crystallizable domain of immunoglobulins. There is a great diversity in terms of possible biological ligands, including the extracellular domains of natural receptors, functionally active peptides, recombinant enzymes, and genetically engineered binding constructs acting as cytokine traps. Due to their highly diverse structures, the analytical characterization of Fc‐Fusion proteins is far more complex than that of monoclonal antibodies and requires the use and development of additional product‐specific methods over conventional generic/platform methods. This can be explained, for example, by the presence of numerous sialic acids, leading to high diversity in terms of isoelectric points and complex glycosylation profiles including multiple N‐ and O‐linked glycosylation sites. In this review, we highlight the wide range of analytical strategies used to fully characterize Fc‐fusion proteins. We also present case studies on the structural assessment of all commercially available Fc‐fusion proteins, based on the features and critical quality attributes of their ligand‐binding domains.     

Can JWH‐210 and JWH‐122 be detected in adipose tissue four weeks after single oral drug administration to rats?

Synthetic cannabinoids such as alkylindole derivatives entered the illicit drug market worldwide a few years ago. Only a few data are available concerning their pharmacokinetics, in particular their distribution and persistence in adipose tissue. For the present study, rats were administered a single 20 mg/kg oral dose of JWH‐210 or JWH‐122. After one month, they were dissected and adipose tissue was taken in order to study whether JWH‐210 and JWH‐122 persisted in this body sample. After extraction, the samples were analyzed by liquid chromatographic–mass spectrometry (LC‐QTrap‐MS). Validation of the analytical method for adipose tissue is also presented. The results of the matrix effects determination ranged between 30.6 and 43.8%. The limits of detection for JWH‐210 and JWH‐122 were 0.8 and 1.0 ng/g and lower limits of quantification were 3.7 and 2.1 ng/g, respectively. Calibration curves ranged from 10 to 75 ng/g for JWH‐210 and from 5 to 50 ng/g for JWH‐122. Intra‐ and interday precision values were lower than 15% and bias values within ±15%. Applying this method, in adipose tissue specimens obtained 4 weeks after single drug administration, JWH‐210 and JWH‐122 were detected in concentrations of 116 and 9 ng/g, respectively. Copyright © 2014 John Wiley & Sons, Ltd.     

Bioanalytical procedures for determination of drugs of abuse in oral fluid

Recent advances in analytical techniques have enabled the detection of drugs and drug metabolites in oral fluid specimens. Although GC–MS is still commonly used in practice, many laboratories have developed and successfully validated methods for LC–MS(–MS) that can detect a large number of compounds in the limited sample volume available. In addition, several enzyme immunoassays have been commercialized for the detection of drugs of abuse in oral fluid samples, enabling the fast screening and selection of presumably positive samples. A number of concerns are discussed, such as the variability in the volume of sample collected and its implications in terms of quantitative measurements, and the drug recoveries of the many different specimen collection systems on the market. Additional considerations that also receive attention are the importance of providing complete validation data with respect to analyte stability, matrix effect, and the choice of collection method.     

Enhancing drug development and clinical studies with patient-centric sampling using microsampling techniques: Opportunities,challenges, and insights into liquid chromatography-mass spectrometry strategies

Microsampling has revolutionized pharmaceutical drug development and clinical research by reducing sample volume requirements, allowing sample collection at home or nontraditional sites, minimizing animal and patient burden, and enabling more flexible study designs. This perspective paper discusses the transformative impact of microsampling and patient-centric sampling (PCS) techniques, emphasizing their advantages in drug development and clinical trials. We highlight the integration of liquid chromatography-mass spectrometry (LC–MS) strategies for analyzing PCS samples, focusing on our research experience and a review of current literatures. The paper reviews commercially available PCS devices, their regulatory status, and their application in clinical trials, underscoring the benefits of PCS in expanding patient enrollment diversity and improving study designs. We also address the operational challenges of implementing PCS, including the need for bridging studies to ensure data comparability between traditional and microsampling methods, and the analytical challenges posed by PCS samples. The paper proposes future directions for PCS, including the development of global regulatory standards, technological advancements to enhance user experience, the increased concern of sustainability and patient data privacy, and the integration of PCS with other technologies for improved performance in drug development and clinical studies. By advancing microsampling and PCS techniques, we aim to foster patient-centric approaches in pharmaceutical sciences, ultimately enhancing patient care and treatment efficacy.